High-performance liquid chromatography coupled with negative ion tandem mass spectrometry for determination of pravastatin in human plasma

Zhu, Zhigang; Neirinck, Len

doi:10.1016/s1570-0232(02)00526-3

Cited by 34 publications

(29 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies, for analysis of pitavastatin, liquidliquid extraction (Chung et al, 2005;Kojima et al, 1999) or column switching (Kojima et al, 1999) methods have been used for cleaning up pitavastatin in plasma samples, whereas a solid-phase extraction method has been reported for cleaning of pravastatin (Kawabata et al, 2005;Zhu and Neirinck, 2003;Miao and Metcalfe, 2003;Mulvana et al, 2000). We found that pitavastatin could be also purified by solid-phase extraction method, and that this was much simpler than the pretreatment procedure used previously (Chung et al, 2005;Kojima et al, 1999).…”

Section: Pharmacokinetics Of Pravastatin and Pitavastatinmentioning

confidence: 72%

“…Therefore, pravastatin and pitavastatin may be used as useful probe substrates for study of OATP1B1 genetic polymorphism and OATP1B1-related drug-drug interaction. Several methods have been described for the analysis of either pravastatin alone (Kawabata et al, 2005;Zhu and Neirinck, 2003), or pravastatin with other statins such as atorvastatin, lovastatin, simvastatin and rosuvastatin (Pasha et al, 2006;Miao and Metcalfe, 2003) in plasma using LC-MS/MS employing solidphase extraction. However, the previously published HPLC methods for quantitation of pitavastatin require a large volume (1.0 mL) of plasma and a tedious liquidliquid extraction step (Chung et al, 2005;Kojima et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of two HMG‐CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study

Deng

Kim

Song

et al. 2007

Biomedical Chromatography

View full text Add to dashboard Cite

We developed a method for determining pravastatin or pitavastatin, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, in plasma using liquid chromatography and tandem mass spectrometry (LC-MS/MS). Pravastatin, pitavastatin and the internal standard fluvastatin were extracted from plasma with solid-phase extraction columns and eluted with methanol. After drying the organic layer, the residue was reconstituted in mobile phase (acetonitrile:water, 90:10, v/v) and injected onto a reversed-phase C(18) column. The isocratic mobile phase was eluted at 0.2 mL/min. The ion transitions recorded in multiple reaction monitoring mode were m/z 423 --> 101, 420 --> 290 and 410 --> 348 for pravastatin, pitavastatin and fluvastatin, respectively. The coefficient of variation of the assay precision was less than 12.4%, the accuracy exceeded 89%. The limit of detection was 1 ng/mL for all analytes. This method was used to measure the plasma concentration of pitavastatin or pravastatin from healthy subjects after a single 4 mg oral dose of pitavastatin or 40 mg oral dose of pravastatin. This is a very simple, sensitive and accurate analytic method to determine the pharmacokinetic profiles of pitavastatin or pravastatiny.

show abstract

Section: Pharmacokinetics Of Pravastatin and Pitavastatinmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Determination of two HMG‐CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study

Deng

Kim

Song

et al. 2007

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…Literature survey reveals that pravastatin is official in British Pharmacopoeia (British Pharmacopoeia, 2007a). Several analytical methods are available for the estimation of pravastatin in bulk, pharmaceutical dosage forms and biological matrices, these include UV spectrophotometry (Balaji and Suman, 2009;Kunjan et al, 2014), visible spectrophotometry (Kalvikkarasi et al, 2009;Safwan and Mouhammed, 2011), HPLC (Bauer et al, 2005;Önal and Sagirli, 2006;Brain-Isasi et al, 2008;Safwan et al, 2008;Raj et al, 2010;Jane and Janivishal, 2013;Vania, 2014), LC-MS (Mulvana et al, 2000;Zhu and Neirinck, 2003;Kawabata et al, 2005;Sampath et al, 2011), capillary electrophoresis (Kircali et al, 2004;Nigovic and Vegar, 2008) and voltammetry (Nigović, 2006). Aspirin, chemically known as 2-acetyloxybenzoic acid (Figure 2), is a nonsteroidal anti-inflammatory drug used in the temporary relief of various forms of pain and inflammation associated with various conditions (Valentin and Joseph, 2011).…”

Section: Pravastatin Chemically Known As (3r5r)-7-[(1s2s6s8s8armentioning

confidence: 99%

Stability Indicating HPLC Method for the Simultaneous Quantification of Aspirin and Pravastatin in bulk and Tablets: Method Development and Validation

2017

J App Pharma Sci

View full text Add to dashboard Cite

The aim of the present study was to develop and validate a stability indicating HPLC method for the simultaneous determination of aspirin and pravastatin in bulk and pharmaceutical dosage forms. The chromatographic separation of aspirin, pravastatin and their degradation products was achieved on Phenomex C18 column with mixture of water, acetonitrile and acetic acid (40:59:01, v/v/v) as mobile phase in an isocratic elution mode at a flow rate of 1.5 mL/min. The method exhibited linearity in the concentration range of 20.5 -61.5 μg/mL and 10-30 μg/mL for aspirin and pravastatin, respectively. The limits of detection and quantification were 0.204μg/mL and 0.680 μg/mL for aspirin and 0.077 μg/mL and 0.256 μg/mL for pravastatin, respectively. The developed method was validated with respect to accuracy, precision, selectivity, specificity and robustness. All the parameters examined were within the acceptance limits. The stability-indicating power of the proposed method was proved by subjecting the drugs to hydrolytic (acid and base), oxidative, photolytic and dry heat stress conditions. The developed method was found to be suitable for routine analysis of aspirin and pravastatin simultaneous in the presence of its stress degradation products.

show abstract

“…Several HPLC methods have been developed for estimation of PV using either UV detection without derivatization (Whigan et al, 1989;Iacona et al, 1994;Otter and Mignat, 1998;Sigurbjornsson et al, 1998;Li et al, 1999Li et al, , 2001Siekmeier et al, 2000;Bauer et al, 2005) or laser-induced fluorescence detection following derivatization (Dumousseaux et al, 1994). In addition, several HPLC-MS/MS methods were reported for quantitation of PV alone (Jemal et al, 1998;Hedman et al, 2003;Zhu and Neirinck 2003) or along with its metabolites from human plasma (Kawabata et al, 1998;Mulvana et al, 2000) and also from rat plasma and mouse, rat, monkey and human serum (Jemal et al, 1998). All these LC-MS/MS methods provide good specificity and sensitivity.…”

Section: Pravastatinmentioning

confidence: 99%

Analysis of five HMG‐CoA reductase inhibitors— atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies

Pasha

Syed

Basha

et al. 2005

Biomedical Chromatography

View full text Add to dashboard Cite

A specific, accurate, precise and reproducible high-performance liquid chromatographic (HPLC) method was developed and validated for the simultaneous quantitation of five 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, viz. atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin, in pharmaceutical formulations and extended the application to in vitro metabolism studies of these statins. Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature. The mobile phase consisted of 0.01 m ammonium acetate (pH 5.0), acetonitrile and methanol. Theophylline was used as an internal standard (IS). The HMG-CoA reductase inhibitors and their metabolites were monitored at a wavelength of 237 nm. Drugs were found to be 89.6-105.6% of their label's claim in the pharmaceutical formulations. For in vitro metabolism studies the reaction mixtures were extracted with simple liquid-liquid extraction using ethyl acetate. Baseline separation of statins and their metabolites along with IS free from endogenous interferences was achieved. Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively. The proposed method is simple, selective and could be applicable for routine analysis of HMG-CoA reductase inhibitors in pharmaceutical preparations as well as in vitro metabolism studies.

show abstract

High-performance liquid chromatography coupled with negative ion tandem mass spectrometry for determination of pravastatin in human plasma

Cited by 34 publications

References 9 publications

Determination of two HMG‐CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study

Determination of two HMG‐CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study

Stability Indicating HPLC Method for the Simultaneous Quantification of Aspirin and Pravastatin in bulk and Tablets: Method Development and Validation

Analysis of five HMG‐CoA reductase inhibitors— atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies

Contact Info

Product

Resources

About